Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.40 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.40 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP4B1 | P13584 | 1/20 | 0.40 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.40 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.40 |
| ▸ | CYP2A7 | P20853 | 1/20 | 0.40 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.40 |
| ▸ | CYP2F1 | P24903 | 1/20 | 0.40 |
| ▸ | CYP2C18 | P33260 | 1/20 | 0.40 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.40 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.40 |
| ▸ | CYP4F8 | P98187 | 1/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20314895 | 0.75 | CYP1A2 (0.53) | CYP1A2CYP2A6MAPTLMNAACHE | |
| SCHEMBL23735859 | 0.73 | CYP1A2 (0.62) | CYP1A2CYP2A6CYP3A4LMNAACHE | |
| SCHEMBL3433939 | 0.71 | ALDH1A1 (0.48) | CYP1A2CYP3A4CYP2C9CYP2C19CYP1A1 | |
| SCHEMBL9225176 | 0.70 | CDC25B (0.51) | CYP1A2MAPTLMNAL3MBTL1ALDH1A1 | |
| SCHEMBL19122751 | 0.70 | ALDH1A1 (0.42) | CYP3A4CYP2D6MAPTLMNAMEN1 | |
| SCHEMBL2737299 | 0.70 | CYP2D6 (0.47) | CYP1A2CYP2A6CYP2D6ACHEMEN1 | |
| SCHEMBL13635146 | 0.69 | CDC25B (0.40) | CYP1A2CYP2A6TNKSMAPTLMNA | |
| SCHEMBL2971769 | 0.68 | POLB (0.47) | CYP1A2CYP2A6LMNAMEN1KMT2A | |
| SCHEMBL17522141 | 0.67 | FKBP1A (0.45) | CYP3A4LMNAL3MBTL1ALDH1A1 | |
| SCHEMBL4203130 | 0.67 | CYP1A2 (0.59) | CYP1A2CYP2A6ACHEALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233966-A1 | Analogues of the Azinomycins as Anti-Tumour Agents and as Prodrugs | SCHOOL OF PHARMACY, UNIVERSITY OF LONDON (GB) | 2009-09-17 | — | — | US | disclosed |
| US-20090233966-A1 | Analogues of the Azinomycins as Anti-Tumour Agents and as Prodrugs | SCHOOL OF PHARMACY, UNIVERSITY OF LONDON (GB) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233966-A1 | Analogues of the Azinomycins as Anti-Tumour Agents and as Prodrugs | CYP1B1, AZI2, ECI1 | CYP1A2 11/4885CYP2A6 95/4885CYP3A4 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.